Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

NCT05296005 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI Decision

Conditions

Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage IIA Gastric Cancer AJCC v8
Clinical Stage IIB Gastric Cancer AJCC v8
Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Gastric Adenocarcinoma
Pathologic Stage IB Gastric Cancer AJCC v8
Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage II Gastric Cancer AJCC v8
Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIA Gastric Cancer AJCC v8
Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIB Gastric Cancer AJCC v8
Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage III Gastric Cancer AJCC v8
Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIA Gastric Cancer AJCC v8
Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIB Gastric Cancer AJCC v8
Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIC Gastric Cancer AJCC v8
Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

Interventions

DRUG: Capecitabine
DRUG: Docetaxel
DRUG: Fluorouracil
DRUG: Leucovorin
DRUG: Oxaliplatin
RADIATION: Radiation Therapy
PROCEDURE: Surgical Procedure

Sponsor

Ohio State University Comprehensive Cancer Center